milrinone has been researched along with quinazolines in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (64.71) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebbert, M; Janssens, WJ; Leidig, A; Meuter, C; Peters, T; Wilffert, B; Wilhelm, D | 1 |
| D'Aubioul, JA; de Chaffoy de Courcelles, DR; De Clerck, FF; Hermans, CF; Vandeplassche, GM; Wouters, LJ | 1 |
| Janssen, PA; Reneman, RS; Van de Water, A; Xhonneux, R | 1 |
| Braunwald, E; Colucci, WS; Wright, RF | 1 |
| Decker, N; Grima, M; Schwartz, J | 2 |
| Gillespie, E | 1 |
| Houslay, MD; Price, B; Pyne, NJ | 1 |
| Komajda, M | 1 |
| Chatterjee, K; Daly, PA; Kereiakes, D; Modin, G; Simonton, CA | 1 |
| Baryla, UM; Fleming, JS; Stanton, HC | 1 |
| Alvarez, R; Bruno, JJ; Johnson, L; Jones, GH; Lee, CH; Montgomery, W; Strosberg, AM; Venuti, MC | 1 |
| Ferguson, JJ; Grossman, W; McKay, RG; Miller, MJ; Momomura, S; Pasternak, RC; Sahagian, P | 1 |
| Carlier, J; D'Orio, V; el Allaf, D | 1 |
| Heaslip, R; Molnar-Kimber, K; Weichman, B; Yonno, L | 1 |
| de Chaffoy de Courcelles, D; Roevens, P | 1 |
| Casadei, B; Musialek, P; Paterson, DJ; Rigg, L; Terrar, DA | 1 |
2 review(s) available for milrinone and quinazolines
| Article | Year |
|---|---|
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Coenzymes; Enoximone; Heart; Heart Failure; Hemodynamics; Humans; Imidazoles; Injections, Intravenous; Milrinone; Nifedipine; Oxyfedrine; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Quinazolines; Ubiquinone | 1986 |
The new inotropic phosphodiesterase inhibitors.
Topics: Aminopyridines; Amrinone; Calcium; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Stimulation, Chemical; Time Factors; Xanthines | 1984 |
15 other study(ies) available for milrinone and quinazolines
| Article | Year |
|---|---|
In vitro pharmacology of R 80122, a novel phosphodiesterase inhibitor.
Topics: Action Potentials; Animals; Benzimidazoles; Carbachol; Female; Guinea Pigs; Heart Rate; Imidazoles; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Norepinephrine; Ouabain; Oxindoles; Papillary Muscles; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Stimulation, Chemical; Vasodilator Agents | 1992 |
Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
Topics: Analysis of Variance; Animals; Cardiotonic Agents; Dogs; Enoximone; Female; Heart Ventricles; Hemodynamics; Imidazoles; In Vitro Techniques; Isoenzymes; Male; Milrinone; Myocardial Contraction; Myocardial Reperfusion; Myocardium; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridones; Quinazolines | 1992 |
Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure.
Topics: Animals; Blood Pressure; Cardiac Output, Low; Dogs; Female; Heart Rate; Hemodynamics; Imidazoles; Infusions, Intravenous; Male; Milrinone; Myocardial Ischemia; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Vascular Resistance; Ventricular Function, Left | 1992 |
Inhibition of some new cardiotonic agents by tetrodotoxin.
Topics: Animals; Cardiotonic Agents; Dihydropyridines; Dose-Response Relationship, Drug; Guinea Pigs; Heart Atria; Imidazoles; In Vitro Techniques; Ion Channels; Isoproterenol; Milrinone; Myocardial Contraction; Protoveratrines; Pyridines; Pyridones; Quinazolines; Tetrodotoxin | 1986 |
Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Blood Platelets; Dose-Response Relationship, Drug; Humans; Milrinone; Platelet Aggregation Inhibitors; Pyridones; Quinazolines; Theophylline | 1988 |
Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Amrinone; Animals; Carbamates; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Dogs; Kinetics; Milrinone; Myocardium; Peptide Hydrolases; Pyridazines; Pyridones; Quinazolines; Trypsin | 1987 |
[New cardiotonic agents].
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Colforsin; Deoxyepinephrine; Humans; Imidazoles; Levodopa; Milrinone; Practolol; Prenalterol; Propanolamines; Pyridones; Quinazolines; Xamoterol | 1985 |
Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiotonic Agents; Death, Sudden; Drug Evaluation; Enoximone; Female; Heart Failure; Humans; Imidazoles; Male; Middle Aged; Milrinone; Pyridones; Quinazolines; Retrospective Studies; Time Factors | 1987 |
The anesthetized ferret, an in vivo model for evaluating inotropic activity: effects of milrinone and anagrelide.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Carnivora; Drug Evaluation, Preclinical; Electrocardiography; Ferrets; Heart Rate; Milrinone; Myocardial Contraction; Pyridones; Quinazolines; Species Specificity | 1988 |
RS-82856, a selective phosphodiesterase inhibitor with inotropic, afterload reduction and antithrombotic properties.
Topics: Animals; Dogs; Fibrinolytic Agents; Heart Rate; Imidazoles; Milrinone; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Quinolines; Vasodilation | 1987 |
Assessment of left ventricular end-systolic pressure-volume relations with an impedance catheter and transient inferior vena cava occlusion: use of this system in the evaluation of the cardiotonic effects of dobutamine, milrinone, Posicor and epinephrine.
Topics: Animals; Blood Pressure; Cardiography, Impedance; Cardiotonic Agents; Constriction; Dobutamine; Dogs; Drug Evaluation, Preclinical; Epinephrine; Heart Rate; Milrinone; Myocardial Contraction; Pyridones; Quinazolines; Stroke Volume; Swine; Vena Cava, Inferior | 1986 |
Effect of some new cardiotonic agents on synaptosomal sodium uptake.
Topics: Animals; Cardiotonic Agents; Guinea Pigs; Heart Atria; Imidazoles; Male; Milrinone; Protoveratrines; Pyridones; Quinazolines; Rats; Rats, Inbred Strains; Sodium; Synaptosomes; Tetrodotoxin; Theophylline; Time Factors | 1986 |
Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors.
Topics: Cell Survival; Cells, Cultured; Endotoxins; Humans; Interleukin-1; Isoenzymes; Milrinone; Monocytes; Phosphodiesterase Inhibitors; Purinones; Pyridones; Pyrrolidinones; Quinazolines; Rolipram; Tumor Necrosis Factor-alpha; Vinca Alkaloids | 1993 |
Cyclic AMP-phosphodiesterase IIIA1 inhibitors decrease cytosolic Ca2+ concentration and increase the Ca2+ content of intracellular storage sites in human platelets.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminoquinolines; Blood Platelets; Calcium; Chlortetracycline; Cytosol; Enoximone; Heart; Homeostasis; Humans; Imidazoles; Milrinone; Phosphodiesterase Inhibitors; Pyridones; Quinazolines | 1993 |
Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors.
Topics: Animals; Calcium; Carbazoles; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guinea Pigs; Heart Atria; Heart Rate; Hydrazines; Indoles; Isoquinolines; Male; Milrinone; Models, Biological; Molsidomine; Nitric Oxide Donors; Nitrogen Oxides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Platelet Aggregation Inhibitors; Pyrroles; Quinazolines; Ryanodine; Sarcoplasmic Reticulum; Signal Transduction; Spectrometry, Fluorescence; Sulfonamides; Superoxide Dismutase; Tetrahydroisoquinolines; Thionucleotides; Time Factors; Vasodilator Agents | 2000 |